The $21 million new building, at 5490 Cobbler Way, replaces the cancer practice’s longtime western suburban facility on the ...

Sickle cell carriers are at a slightly increased risk of blood clots, but the overall risk is still low, a study found.

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

KUWAIT CITY, Sept 19: Kuwait’s Minister of Health, Dr. Ahmed Al-Awadhi, alongside Undersecretary Dr. Abdulrahman Al-Mutairi, ...

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with cancer want information and advice early in the ...

When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those ...

“For far too many children with cancer, clinical trials are their only chance at survival,” says Dr. Catherine Vézina. A ...